{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000004","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.960121+00:00","generated_at":"2026-06-07T01:32:04.524984+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Novocure completes enrollment in Phase 3 TRIDENT trial for newly diagnosed glioblastoma; data expected 2026","bullets":["Final patient enrolled in global Phase 3 TRIDENT trial (950 patients) evaluating Optune Gio concurrent with radiation + temozolomide for newly diagnosed GBM.","Patients randomized to TTFields + TMZ + radiation vs TMZ + radiation for 6 weeks, then all receive standard care (TTFields + maintenance TMZ).","Primary endpoint is overall survival; secondary endpoints include PFS, safety, quality of life, and radiological response.","Top-line data from the trial is anticipated in 2026; enrollment began in December 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000004","json":"https://secwatch.observer/filing/0001645113-24-000004.json","markdown":"https://secwatch.observer/filing/0001645113-24-000004.md","text":"https://secwatch.observer/filing/0001645113-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000004/0001645113-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000004/nvcr-20240109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:32:04.524984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}